Optimizing Treatment on Idiopathic Inflammatory Myopathies

University of Sao Paulo

Status: Enrolling

Conditions: Idiopathic Inflammatory Myopathies

Treatments: Drug: Intravenous Infusion

Study type: Observational

Funder types: Other

Identifiers

NCT03092180

MYO-HCFMUSP-01

Details and patient eligibility

About

As a T2T, our patients with idiopathic inflammatory myopathies will receive pulse therapies with methyprednisolone and/or human intravenous immunoglobulin, or only methyprednisolone at disease onset.

This scheme is an internal routine protocol of our Service.

Full description

To compare two groups of patients as described in Brief Summary.

Enrollment: 60 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Idiopathic inflammatory myopathies

Exclusion criteria

• Inclusion body myositis, muscular dystrophies, neoplasia-associated myopathies, overlapped myopathies, others myopathies

Trial design

60 participants in 2 patient groups

Idiopathic inflammatory myopathies 1

Description:

Intravenous infusion with methyprednisolone / human intravenous immunoglobulin at disease onset

Treatment:

Drug: Intravenous Infusion

Idiopathic inflammatory myopathies 2

Description:

Intravenous infusion with methyprednisolone at disease onset

Treatment:

Drug: Intravenous Infusion